Provider Reviews

Willow vs LTTL: Telehealth tracking vs compounded GLP-1 care

Quick verdict: Willow vs LTTL offers two different telehealth approaches: Willow focuses on a structured oral GLP-1 weight management program with progress tracking and follow-up; LTTL focuses on clinician-reviewed compounded GLP-1 medications with pharmacy verification and promotional pricing details. Willow starts at 299; LTTL advertises pricing cues including $129, $249 and a starting price of $140 and up to $140 off your first month.

Explore Willow’s tracked program

Core difference: structured follow-up vs compounded medication model

Willow positions its oral GLP-1 program as a structured weight management journey, emphasizing progress tracking tools and follow-up consultations through a licensed telehealth team. LTTL presents clinician-reviewed online weight-management treatment that highlights compounded GLP-1 medications prepared by U.S.A. licensed pharmacies, independent verification in FDA registered labs, and delivery to your door. Both note treatment is available only when a licensed clinician determines it is medically appropriate. Both also include the regulatory qualification that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

Pricing signals and promotional language

Willow lists a starting price of 299. LTTL shows multiple price cues including $249 and $129 and a stated starting price of $140 and promotional language of up to $140 off your first month with a code auto-applied. The captured materials indicate LTTL suggests same price every dose and 4 doses/month in some examples. Exact renewal, eligibility and state coverage terms for LTTL are noted as subject to confirmation; Willow’s shipping, fees, membership and cancellation details were not verified on the captured page.

See LTTL pricing and pharmacy details

Clinical process and quality checks

Willow: Telehealth-first model with a licensed telehealth team, progress tracking tools and follow-up consultations to convert medication effects into a supported weight management journey. The program frames itself as structured support rather than a simple medication subscription. LTTL: Emphasizes compounded GLP-1 medications formulated to help regulate appetite and promote fullness, prepared in state-licensed pharmacies, independently verified in FDA registered labs, and confirmed every 3-6 months to stay within +/- 10% of target strength. Both record that treatment is available only when a licensed clinician determines it is medically appropriate.

Distinctive supported differences

  • Support model: Willow emphasizes progress tracking and follow-up consultations; LTTL emphasizes pharmacy compounding and lab verification.
  • Pricing presentation: Willow lists a 299 starting price; LTTL presents multiple price points and promotional up to $140 off the first month.
  • Medication sourcing: Willow notes that compounded medications, when offered, are not FDA-approved; LTTL states compounded medications are prepared by U.S.A. licensed pharmacies and are not FDA-approved.
  • Delivery and verification: LTTL states medications are delivered to your door and independently verified in FDA registered labs; Willow’s captured page did not verify shipping or delivery details.

Comparison table

Criteria Willow LTTL
Model Telehealth-first weight management with progress tracking and follow-up Clinician-reviewed online treatment with compounded GLP-1 medications
Starting price 299 $140 (pricing cues include $129 and $249; up to $140 off first month)
Medication sourcing Notes compounded medications, when offered, are not FDA-approved Compounded by U.S.A. licensed pharmacies; not FDA-approved
Quality verification Licensed telehealth team and follow-up; no captured lab verification Independent verification in FDA registered labs; confirmed every 3-6 months
Delivery and fees Shipping/fees/membership/cancellation not verified on the captured page Delivered to your door; promotional pricing noted

Patient experience and best-for guidance

Willow frames its offering for users who want structured digital follow-up and behavioral scaffolding alongside oral GLP-1 treatment. LTTL is described as best for people who confirm eligibility, medication, total cost, renewal terms and state availability before enrollment and emphasizes pharmacy compounding and lab verification.

Compare Willow program details

Safety and regulatory notes

Both sources state treatment is available only when a licensed clinician determines it is medically appropriate. Both sources include the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The captured evidence for Willow did not include expanded FAQ answers or verified shipping details; LTTL’s captured landing-page evidence emphasizes verification and delivery claims but cautions that pricing, eligibility, pharmacy, state coverage and renewal terms may change.

Start with Willow’s telehealth flow

Conclusion: Willow vs LTTL

Willow vs LTTL differs mainly by support style and medication sourcing. Choose Willow if you prioritize a telehealth-first program that emphasizes progress tracking and follow-up consultations and you note the listed starting price of 299. Choose LTTL if you prioritize compounded GLP-1 prepared by U.S.A. licensed pharmacies with independent lab verification, delivery to your door, and promotional pricing including up to $140 off your first month. Remember treatment is available only when a licensed clinician determines it is medically appropriate and compounded medications are not FDA-approved.

Ready to Compare Telehealth Providers?

Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.

Compare All Providers →

Related articles

Medical disclaimer: This page is for informational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any treatment. We may earn a commission from partner links on this page - see our advertising disclosure.